These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 28303260)

  • 1. Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.
    Voutilainen MH; De Lorenzo F; Stepanova P; Bäck S; Yu LY; Lindholm P; Pörsti E; Saarma M; Männistö PT; Tuominen RK
    eNeuro; 2017; 4(1):. PubMed ID: 28303260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.
    Voutilainen MH; Bäck S; Peränen J; Lindholm P; Raasmaja A; Männistö PT; Saarma M; Tuominen RK
    Exp Neurol; 2011 Mar; 228(1):99-108. PubMed ID: 21185834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson's Disease.
    Huotarinen A; Penttinen AM; Bäck S; Voutilainen MH; Julku U; Piepponen TP; Männistö PT; Saarma M; Tuominen R; Laakso A; Airavaara M
    Neuroscience; 2018 Mar; 374():250-263. PubMed ID: 29408408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
    Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
    Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease.
    Voutilainen MH; Bäck S; Pörsti E; Toppinen L; Lindgren L; Lindholm P; Peränen J; Saarma M; Tuominen RK
    J Neurosci; 2009 Jul; 29(30):9651-9. PubMed ID: 19641128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
    Aoi M; Date I; Tomita S; Ohmoto T
    Neurosci Res; 2000 Apr; 36(4):319-25. PubMed ID: 10771110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.
    Lindholm P; Voutilainen MH; Laurén J; Peränen J; Leppänen VM; Andressoo JO; Lindahl M; Janhunen S; Kalkkinen N; Timmusk T; Tuominen RK; Saarma M
    Nature; 2007 Jul; 448(7149):73-7. PubMed ID: 17611540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model.
    Ren X; Zhang T; Gong X; Hu G; Ding W; Wang X
    Exp Neurol; 2013 Oct; 248():148-56. PubMed ID: 23764500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
    Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor.
    Kirik D; Rosenblad C; Björklund A
    Eur J Neurosci; 2000 Nov; 12(11):3871-82. PubMed ID: 11069582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
    Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
    Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA.
    Konieczny J; Czarnecka A; Lenda T; Kamińska K; Antkiewicz-Michaluk L
    Neuroscience; 2017 Jan; 340():308-318. PubMed ID: 27826109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
    Jalewa J; Sharma MK; Gengler S; Hölscher C
    Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinnamon and its Metabolite Protect the Nigrostriatum in a Mouse Model of Parkinson's Disease Via Astrocytic GDNF.
    Patel D; Jana A; Roy A; Pahan K
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):503-518. PubMed ID: 31119595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
    Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
    Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.
    Requejo C; Ruiz-Ortega JA; Bengoetxea H; Garcia-Blanco A; Herrán E; Aristieta A; Igartua M; Ugedo L; Pedraz JL; Hernández RM; Lafuente JV
    Mol Neurobiol; 2015 Oct; 52(2):846-58. PubMed ID: 26041662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.